Systemic Glucocorticoids for Acute Gout
Corticosteroids should be considered first-line therapy for acute gout flares in patients without contraindications, as they are equally effective as NSAIDs and colchicine but with a superior safety profile and lower cost. 1
Indications for Systemic Glucocorticoids
Use systemic corticosteroids when:
- First-line option for any patient with acute gout without contraindications 1
- Patient has contraindications to NSAIDs (renal disease, heart failure, cirrhosis, GI bleeding risk) 1
- Patient has contraindications to colchicine (renal/hepatic impairment with CYP3A4 or P-glycoprotein inhibitor use) 1
- Patient has cardiovascular disease or heart failure (colchicine is preferred, but short-duration low-dose glucocorticoids are safe alternatives) 2
- Cost is a concern (corticosteroids are among the lowest-cost options) 1
Dosing Regimen
Prednisolone 35 mg daily for 5 days has been successfully validated for treating acute gout 1. This represents the evidence-based standard regimen.
Alternative approaches include:
- Intramuscular triamcinolone acetonide (single injection)
- Oral prednisone with equivalent dosing to prednisolone
The 5-day course is sufficient for most acute flares and minimizes exposure to adverse effects associated with longer-term use.
Efficacy Evidence
High-quality evidence demonstrates that corticosteroids are as effective as NSAIDs for pain reduction in acute gout, with no clinically relevant differences in outcomes 1, 3. Moderate-quality evidence from head-to-head trials shows:
- No difference in pain scores at <7 days or ≥7 days compared to NSAIDs 3
- No difference in time to disease resolution 3
- Equal response rates to therapy 3
Safety Profile
Corticosteroids demonstrate superior safety compared to NSAIDs for acute gout treatment 1, 3:
- Lower risk of indigestion (RR 0.50) 3
- Lower risk of nausea (RR 0.25) 3
- Lower risk of vomiting (RR 0.11) 3
- No evidence of increased GI bleeding risk compared to NSAIDs 3
Short-term use (5 days) minimizes the risks associated with chronic corticosteroid therapy.
Contraindications and Precautions
Absolute contraindication:
- Systemic fungal infections 1
Use with caution in:
- Uncontrolled diabetes (monitor glucose levels closely—expect transient elevation) 1
- Active infections (immune suppression risk) 1
- Severe psychiatric disorders (risk of dysphoria, mood disorders) 1
Important clinical considerations:
- Short-term use (5 days) carries minimal risk of the adverse effects associated with long-term corticosteroid therapy 1
- Fluid retention may occur—monitor in patients with heart failure 1
- The brief duration makes adrenal suppression unlikely
Comparison to Other Agents
The 2017 ACP guideline provides a strong recommendation (high-quality evidence) that clinicians choose between corticosteroids, NSAIDs, or colchicine for acute gout 1. However, the guideline specifically states that "corticosteroids should be considered as first-line therapy in patients without contraindications because they are generally safer and a low-cost treatment option" 1.
This recommendation is based on:
- Equal efficacy to NSAIDs and colchicine 1, 3, 4
- Fewer adverse effects than NSAIDs 1, 3
- Lower cost than colchicine 1
- Broader applicability (fewer contraindications than NSAIDs in patients with comorbidities) 1
Common Pitfalls to Avoid
Don't avoid corticosteroids due to unfounded concerns about short-term use—the 5-day regimen is safe and does not carry the risks of chronic steroid therapy 1, 3
Don't default to NSAIDs in elderly patients or those with renal disease—corticosteroids are safer in these populations 1
Don't use prolonged tapers for acute flares—5 days is sufficient; longer courses increase adverse effect risk without additional benefit 1
Don't withhold treatment while waiting for joint aspiration—if clinical presentation is consistent with gout, initiate treatment promptly 1